002252 上海莱士
已收盘 09-16 15:00:00
资讯
新帖
简况
上海莱士(002252.SZ):“SR604注射液”进入Ⅲ期临床试验
智通财经 · 09-16 19:56
上海莱士(002252.SZ):“SR604注射液”进入Ⅲ期临床试验
上海莱士(002252)9月10日股东户数11.63万户,较上期减少0.28%
证券之星 · 09-16 17:36
上海莱士(002252)9月10日股东户数11.63万户,较上期减少0.28%
股市必读:上海莱士新发布《回购报告书》
证券之星 · 09-11
股市必读:上海莱士新发布《回购报告书》
上海莱士(002252)披露回购报告书,9月10日股价上涨0.2%
证券之星 · 09-10
上海莱士(002252)披露回购报告书,9月10日股价上涨0.2%
上海莱士(002252)8月31日股东户数11.66万户,较上期减少1.2%
证券之星 · 09-09
上海莱士(002252)8月31日股东户数11.66万户,较上期减少1.2%
上海莱士:截至2026年8月31日,公司股东总户数为116,589户
证券之星 · 09-09
上海莱士:截至2026年8月31日,公司股东总户数为116,589户
公司问答丨上海莱士:公司不存在在美国投资血液制品生产的相关情形
格隆汇 · 09-07
公司问答丨上海莱士:公司不存在在美国投资血液制品生产的相关情形
上海莱士SR604拟纳入罕见病创新药研发试点,临床研究持续推进
证券之星 · 09-03
上海莱士SR604拟纳入罕见病创新药研发试点,临床研究持续推进
上海莱士(002252)披露2026年第二次临时股东会会议决议公告,9月1日股价上涨2.26%
证券之星 · 09-01
上海莱士(002252)披露2026年第二次临时股东会会议决议公告,9月1日股价上涨2.26%
上海莱士(002252.SZ):SR604注射液拟纳入“关爱计划-延伸”试点项目
智通财经 · 08-31
上海莱士(002252.SZ):SR604注射液拟纳入“关爱计划-延伸”试点项目
上海莱士(002252)8月20日股东户数11.8万户,较上期增加0.5%
证券之星 · 08-28
上海莱士(002252)8月20日股东户数11.8万户,较上期增加0.5%
上海莱士:广西莱士目前处于试生产阶段
证券之星 · 08-28
上海莱士:广西莱士目前处于试生产阶段
上海莱士:截至2026年8月20日,公司股东总户数为118,000户
证券之星 · 08-28
上海莱士:截至2026年8月20日,公司股东总户数为118,000户
股市必读:上海莱士新发布《关于回购股份事项股东会股权登记日前十名股东及前十名无限售条件股东持股情况的公告》
证券之星 · 08-28
股市必读:上海莱士新发布《关于回购股份事项股东会股权登记日前十名股东及前十名无限售条件股东持股情况的公告》
股市必读:上海莱士新发布《2026年半年度报告》
证券之星 · 08-26
股市必读:上海莱士新发布《2026年半年度报告》
上海莱士(002252)披露聘任财务负责人公告,8月25日股价上涨1.87%
证券之星 · 08-25
上海莱士(002252)披露聘任财务负责人公告,8月25日股价上涨1.87%
上海莱士最新公告:上半年净利润6.61亿元同比下降35.8%
证券之星 · 08-24
上海莱士最新公告:上半年净利润6.61亿元同比下降35.8%
上海莱士(002252)披露全资子公司“蛋白C”临床试验申请获得受理的公告,8月24日股价下跌0.21%
证券之星 · 08-24
上海莱士(002252)披露全资子公司“蛋白C”临床试验申请获得受理的公告,8月24日股价下跌0.21%
上海莱士:全资子公司“蛋白C”临床试验申请获受理 目前国内尚无同类人蛋白C制剂获批上市
格隆汇 · 08-21
上海莱士:全资子公司“蛋白C”临床试验申请获受理 目前国内尚无同类人蛋白C制剂获批上市
股市必读:上海莱士(002252)股东户数11.74万户,较上期减少0.3%
证券之星 · 08-20
股市必读:上海莱士(002252)股东户数11.74万户,较上期减少0.3%
加载更多
公司概况
公司名称:
上海莱士血液制品股份有限公司
所属行业:
医药制造业
上市日期:
2008-06-23
主营业务:
上海莱士血液制品股份有限公司的主营业务是血液制品的生产和销售。公司的主要产品是人血白蛋白、静注人免疫球蛋白、特异性免疫球蛋白、凝血因子类产品。公司先后获评“上海市外商投资先进技术企业”“高新技术企业”,并设立“院士专家工作站”,彰显在技术研发与质量管控领域的领先地位;公司及旗下南岳生物先后斩获第九届上海市奉贤区区长质量奖金奖和“第八届湖南省省长质量奖”。
发行价格:
12.81
{"stockData":{"symbol":"002252","market":"SZ","secType":"STK","nameCN":"上海莱士","latestPrice":4.85,"timestamp":1789542228000,"preClose":4.91,"halted":0,"volume":31492538,"delay":0,"changeRate":-0.0122,"floatShares":6588000000,"shares":6593000000,"eps":0.1833,"marketStatus":"已收盘","change":-0.06,"latestTime":"09-16 15:00:00","open":4.89,"high":4.9,"low":4.8,"amount":152000000,"amplitude":0.0204,"askPrice":4.86,"askSize":3045,"bidPrice":4.85,"bidSize":1531,"shortable":0,"etf":0,"ttmEps":0.1833,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789608600000},"marketStatusCode":5,"adr":0,"adjPreClose":4.91,"symbolType":"stock","openAndCloseTimeList":[[1789522200000,1789529400000],[1789534800000,1789542000000]],"highLimit":5.4,"lowLimit":4.42,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":6592672885,"isCdr":false,"pbRate":1,"roa":"--","peRate":26.459356,"roe":"2.04%","epsLYR":0.24,"committee":-0.145962,"marketValue":31974000000,"turnoverRate":0.0048,"status":1,"floatMarketCap":31953000000},"requestUrl":"/m/hq/s/002252","defaultTab":"news","newsList":[{"id":"2667988673","title":"上海莱士(002252.SZ):“SR604注射液”进入Ⅲ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2667988673","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667988673?lang=zh_cn&edition=full","pubTime":"2026-09-16 19:56","pubTimestamp":1789559791,"startTime":"0","endTime":"0","summary":"智通财经APP讯,上海莱士 发布公告,公司在研产品“SR604注射液”于近日在国家药品监督管理局药物临床试验登记与信息公示平台公示了“血友病A/B患者出血发作的预防治疗”Ⅲ期临床试验登记信息,试验名称:评价SR604注射液在有或无抑制物的血友病A/B患者中预防治疗的有效性和安全性的单臂、多中心Ⅲ期临床试验试验目的:评价SR604注射液在有或无抑制物的血友病A/B患者中预防治疗的有效性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497035.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PSYK","IBBQ","BK0028","IBBJ","BK0196","BK0188","MDTX","BK0239","BK0046","002252","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667601750","title":"上海莱士(002252)9月10日股东户数11.63万户,较上期减少0.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2667601750","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667601750?lang=zh_cn&edition=full","pubTime":"2026-09-16 17:36","pubTimestamp":1789551397,"startTime":"0","endTime":"0","summary":"证券之星消息,近日上海莱士披露,截至2026年9月10日公司股东户数为11.63万户,较8月31日减少324.0户,减幅为0.28%。在生物制品行业个股中,上海莱士股东户数高于行业平均水平,截至9月10日,生物制品行业平均股东户数为3.59万户。从股价来看,2026年8月31日至2026年9月10日,上海莱士区间涨幅为2.67%,在此期间股东户数减少324.0户,减幅为0.28%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091600027790.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0188","BK0196","002252","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666597722","title":"股市必读:上海莱士新发布《回购报告书》","url":"https://stock-news.laohu8.com/highlight/detail?id=2666597722","media":"证券之星","labels":["buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666597722?lang=zh_cn&edition=full","pubTime":"2026-09-11 01:24","pubTimestamp":1789061054,"startTime":"0","endTime":"0","summary":"截至2026年9月10日收盘,上海莱士报收于5.0元,上涨0.2%,换手率0.56%,成交量36.7万手,成交额1.82亿元。当日关注点交易信息汇总:9月10日主力资金净流入1067.71万元,占总成交额5.86%。公司公告汇总:上海莱士拟以集中竞价方式回购股份,金额2.5亿–5亿元,价格不超7.18元/股,回购股份将用于注销并减少注册资本。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100002181.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0188","BK0196","002252","BK0028","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666561140","title":"上海莱士(002252)披露回购报告书,9月10日股价上涨0.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666561140","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666561140?lang=zh_cn&edition=full","pubTime":"2026-09-10 17:31","pubTimestamp":1789032713,"startTime":"0","endTime":"0","summary":"截至2026年9月10日收盘,上海莱士报收于5.0元,较前一交易日上涨0.2%,最新总市值为329.63亿元。该股当日开盘5.01元,最高5.03元,最低4.92元,成交额达1.82亿元,换手率为0.56%。近日,上海莱士披露《回购报告书》。本次回购股份将用于注销并减少注册资本。回购实施期限为自股东会审议通过之日起12个月内。公司已开立回购专用证券账户,相关审议程序已履行完毕。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091000031566.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0188","002252","BK0239","BK0046","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666058976","title":"上海莱士(002252)8月31日股东户数11.66万户,较上期减少1.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666058976","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666058976?lang=zh_cn&edition=full","pubTime":"2026-09-09 17:27","pubTimestamp":1788946046,"startTime":"0","endTime":"0","summary":"证券之星消息,近日上海莱士披露,截至2026年8月31日公司股东户数为11.66万户,较8月20日减少1411.0户,减幅为1.2%。在生物制品行业个股中,上海莱士股东户数高于行业平均水平,截至8月31日,生物制品行业平均股东户数为3.58万户。从股价来看,2026年8月20日至2026年8月31日,上海莱士区间跌幅为3.18%,在此期间股东户数减少1411.0户,减幅为1.2%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900029337.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0196","BK0188","BK0046","002252","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666301035","title":"上海莱士:截至2026年8月31日,公司股东总户数为116,589户","url":"https://stock-news.laohu8.com/highlight/detail?id=2666301035","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666301035?lang=zh_cn&edition=full","pubTime":"2026-09-09 11:38","pubTimestamp":1788925084,"startTime":"0","endTime":"0","summary":"证券之星消息,上海莱士(002252)09月08日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好!请问截止8月31号,公司的股东人数是多少?谢谢上海莱士回复:感谢您的关注! 截至2026年8月31日,公司股东总户数为116,589户。 谢谢。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900015217.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0196","BK0046","BK0188","BK0028","002252"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665318157","title":"公司问答丨上海莱士:公司不存在在美国投资血液制品生产的相关情形","url":"https://stock-news.laohu8.com/highlight/detail?id=2665318157","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665318157?lang=zh_cn&edition=full","pubTime":"2026-09-07 16:59","pubTimestamp":1788771578,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0028","002252","BK0239","BK0196","BK0046","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664871681","title":"上海莱士SR604拟纳入罕见病创新药研发试点,临床研究持续推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2664871681","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664871681?lang=zh_cn&edition=full","pubTime":"2026-09-03 19:44","pubTimestamp":1788435867,"startTime":"0","endTime":"0","summary":"近日,国家药品监督管理局药品审评中心发布公示,上海莱士靶向活化蛋白C的创新生物药“SR604注射液”拟纳入罕见疾病创新药物研发鼓励试点计划——“关爱计划-延伸”试点项目。目前,SR604已围绕血友病A/B、先天性凝血因子Ⅶ缺乏症、血管性血友病等罕见出血性疾病开展临床研究。上海莱士表示,公司积极对接国内罕见病药物监管创新机制,此次公示拟纳入,提升了公司信心。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026090300037593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0239","BK0188","BK0028","BK0046","002252"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664837297","title":"上海莱士(002252)披露2026年第二次临时股东会会议决议公告,9月1日股价上涨2.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664837297","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664837297?lang=zh_cn&edition=full","pubTime":"2026-09-01 17:31","pubTimestamp":1788255095,"startTime":"0","endTime":"0","summary":"截至2026年9月1日收盘,上海莱士报收于4.98元,较前一交易日上涨2.26%,最新总市值为328.32亿元。该股当日开盘4.87元,最高5.08元,最低4.87元,成交额达2.99亿元,换手率为0.91%。上海莱士于近日披露《2026年第二次临时股东会会议决议公告》。公告显示,公司于2026年8月31日召开第二次临时股东会,审议通过《关于续聘2026年度会计师事务所的议案》及《关于回购公司股份方案的议案》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090100030547.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0239","BK0196","BK0028","002252","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663061640","title":"上海莱士(002252.SZ):SR604注射液拟纳入“关爱计划-延伸”试点项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2663061640","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663061640?lang=zh_cn&edition=full","pubTime":"2026-08-31 21:33","pubTimestamp":1788183230,"startTime":"0","endTime":"0","summary":"智通财经APP讯,上海莱士 发布公告,近日,国家药品监督管理局药品审评中心发布公示,将公司SR604注射液拟纳入“关爱计划-延伸”试点项目,公示时间截至2026年9月4日。据悉,“关爱计划-延伸”项目又名罕见疾病创新药物研发鼓励试点计划,该计划旨在鼓励创新药向临床治疗需求迫切的罕见疾病领域布局,聚焦并解决源头性创新罕见疾病药物研发中的科学问题,提升研发效率。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489878.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","BK0046","BK0028","002252","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662066954","title":"上海莱士(002252)8月20日股东户数11.8万户,较上期增加0.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662066954","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662066954?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:47","pubTimestamp":1787910437,"startTime":"0","endTime":"0","summary":"证券之星消息,近日上海莱士披露,截至2026年8月20日公司股东户数为11.8万户,较8月10日增加582.0户,增幅为0.5%。在生物制品行业个股中,上海莱士股东户数高于行业平均水平,截至8月20日,生物制品行业平均股东户数为3.54万户。从股价来看,2026年8月10日至2026年8月20日,上海莱士区间涨幅为0.2%,在此期间股东户数增加582.0户,增幅为0.5%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800041119.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0028","BK0239","002252","BK0188","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662053900","title":"上海莱士:广西莱士目前处于试生产阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2662053900","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662053900?lang=zh_cn&edition=full","pubTime":"2026-08-28 11:37","pubTimestamp":1787888224,"startTime":"0","endTime":"0","summary":"证券之星消息,上海莱士(002252)08月27日在投资者关系平台上答复投资者关心的问题。投资者提问:广西莱士的生产情况??上海莱士回复:感谢您的关注。广西莱士目前处于试生产阶段,尚未正式投产,其下属浆站采浆工作正常开展,将为后续投产提供血浆原料保障。研发层面相关工作正在有序推进,具体进展及对公司的影响请以公司后续披露的相关公告为准。谢谢您的关注。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800024055.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0028","002252","BK0188","BK0196","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662053163","title":"上海莱士:截至2026年8月20日,公司股东总户数为118,000户","url":"https://stock-news.laohu8.com/highlight/detail?id=2662053163","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662053163?lang=zh_cn&edition=full","pubTime":"2026-08-28 11:33","pubTimestamp":1787887990,"startTime":"0","endTime":"0","summary":"证券之星消息,上海莱士(002252)08月27日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好!请问截止8月20号,公司的股东人数是多少?谢谢上海莱士回复:感谢您的关注! 截至2026年8月20日,公司股东总户数为118,000户。 谢谢。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800023767.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","002252","BK0046","BK0196","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662003689","title":"股市必读:上海莱士新发布《关于回购股份事项股东会股权登记日前十名股东及前十名无限售条件股东持股情况的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2662003689","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662003689?lang=zh_cn&edition=full","pubTime":"2026-08-28 05:43","pubTimestamp":1787866991,"startTime":"0","endTime":"0","summary":"公司公告汇总关于回购股份事项股东会股权登记日前十名股东及前十名无限售条件股东持股情况的公告上海莱士血液制品股份有限公司于2026年7月7日和8月11日召开董事会,审议通过回购公司股份方案及召集2026年第二次临时股东会的议案。本次股东会股权登记日为2026年8月25日。相关信息来源于中国证券登记结算有限责任公司深圳分公司。海盈康(青岛)医疗科技有限公司为第一大股东,持股占比23.47%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800009910.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002252","BK0196","BK0028","BK0046","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662575737","title":"股市必读:上海莱士新发布《2026年半年度报告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2662575737","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662575737?lang=zh_cn&edition=full","pubTime":"2026-08-26 05:27","pubTimestamp":1787693232,"startTime":"0","endTime":"0","summary":"截至2026年8月25日收盘,上海莱士报收于4.9元,上涨1.87%,换手率0.71%,成交量46.53万手,成交额2.26亿元。公司公告汇总:第六届董事会第二十一次会议审议通过《2026年半年度报告全文及摘要》及《关于聘任公司财务负责人的议案》,同意聘请江兰女士为财务负责人,任期至第六届董事会期满。股本股东变化股东户数变动截至2026年8月10日公司股东户数为11.74万户,较7月31日减少355.0户,减幅为0.3%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600008461.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0196","BK0188","BK0046","002252","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662736413","title":"上海莱士(002252)披露聘任财务负责人公告,8月25日股价上涨1.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662736413","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662736413?lang=zh_cn&edition=full","pubTime":"2026-08-25 18:57","pubTimestamp":1787655473,"startTime":"0","endTime":"0","summary":"截至2026年8月25日收盘,上海莱士报收于4.9元,较前一交易日上涨1.87%,最新总市值为323.04亿元。该股当日开盘4.8元,最高4.91元,最低4.78元,成交额达2.26亿元,换手率为0.71%。上海莱士血液制品股份有限公司于2026年8月21日召开第六届董事会第二十一次会议,审议通过《2026年半年度报告全文及摘要》和《关于聘任公司财务负责人的议案》。公司董事会同意聘请江兰女士为财务负责人,任期至第六届董事会期满。相关公告文件已在指定媒体及巨潮资讯网披露。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500040219.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0028","BK0196","BK0188","002252"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661277225","title":"上海莱士最新公告:上半年净利润6.61亿元同比下降35.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661277225","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661277225?lang=zh_cn&edition=full","pubTime":"2026-08-24 23:31","pubTimestamp":1787585461,"startTime":"0","endTime":"0","summary":"上海莱士(002252.SZ)发布2026年半年度报告,实现营业收入32.09亿元,同比下降18.79%;归属于上市公司股东的净利润6.61亿元,同比下降35.8%。公司计划不派发现金红利,不送红股,不以公积金转增股本。注:公司Q2净利润3.45亿,Q1净利润3.16亿,据此计算,Q2净利润环比增长9%。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400038582.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002252"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661206402","title":"上海莱士(002252)披露全资子公司“蛋白C”临床试验申请获得受理的公告,8月24日股价下跌0.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661206402","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661206402?lang=zh_cn&edition=full","pubTime":"2026-08-24 18:12","pubTimestamp":1787566374,"startTime":"0","endTime":"0","summary":"截至2026年8月24日收盘,上海莱士报收于4.81元,较前一交易日下跌0.21%,最新总市值为317.11亿元。近日,上海莱士披露公告显示,其全资子公司广西莱士生物制药有限公司于2026年8月21日收到国家药品监督管理局下发的关于“蛋白C”临床试验申请的《受理通知书》。临床试验申请已获受理,自受理之日起60日内未收到否定或质疑意见可按方案开展临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400025970.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0239","BK0188","BK0028","BK0046","002252"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661298331","title":"上海莱士:全资子公司“蛋白C”临床试验申请获受理 目前国内尚无同类人蛋白C制剂获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2661298331","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661298331?lang=zh_cn&edition=full","pubTime":"2026-08-21 20:27","pubTimestamp":1787315256,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","002252","BK0196","BK0188","BK0028","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660422228","title":"股市必读:上海莱士(002252)股东户数11.74万户,较上期减少0.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660422228","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660422228?lang=zh_cn&edition=full","pubTime":"2026-08-20 01:09","pubTimestamp":1787159352,"startTime":"0","endTime":"0","summary":"截至2026年8月19日收盘,上海莱士报收于4.89元,上涨0.0%,换手率0.6%,成交量39.32万手,成交额1.92亿元。交易信息汇总资金流向8月19日主力资金净流入2737.99万元,占总成交额14.29%;游资资金净流出2015.28万元,占总成交额10.52%;散户资金净流出722.71万元,占总成交额3.77%。股本股东变化股东户数变动截至2026年8月10日公司股东户数为11.74万户,较7月31日减少355户,减幅为0.3%。户均持股数量由上期的5.6万股增加至5.61万股,户均持股市值为28.19万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000001480.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0239","BK0188","BK0028","BK0046","002252"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1789583593339,"stockEarnings":[{"period":"1week","weight":-0.0281},{"period":"1month","weight":-0.0202},{"period":"3month","weight":0.0505},{"period":"6month","weight":-0.1886},{"period":"1year","weight":-0.2903},{"period":"ytd","weight":-0.2277}],"compareEarnings":[{"period":"1week","weight":-0.0152},{"period":"1month","weight":-0.0229},{"period":"3month","weight":-0.0486},{"period":"6month","weight":-0.0165},{"period":"1year","weight":0.0077},{"period":"ytd","weight":-0.0195}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海莱士血液制品股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"116265人(较上一季度减少0.28%)","perCapita":"56665股","listingDate":"2008-06-23","address":"上海市奉贤区望园路2009号","registeredCapital":"659267万元","survey":" 上海莱士血液制品股份有限公司的主营业务是血液制品的生产和销售。公司的主要产品是人血白蛋白、静注人免疫球蛋白、特异性免疫球蛋白、凝血因子类产品。公司先后获评“上海市外商投资先进技术企业”“高新技术企业”,并设立“院士专家工作站”,彰显在技术研发与质量管控领域的领先地位;公司及旗下南岳生物先后斩获第九届上海市奉贤区区长质量奖金奖和“第八届湖南省省长质量奖”。","listedPrice":12.81},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"上海莱士(002252)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供上海莱士(002252)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"上海莱士,002252,上海莱士股票,上海莱士股票老虎,上海莱士股票老虎国际,上海莱士行情,上海莱士股票行情,上海莱士股价,上海莱士股市,上海莱士股票价格,上海莱士股票交易,上海莱士股票购买,上海莱士股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"上海莱士(002252)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供上海莱士(002252)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}